| Identification | Back Directory | [Name]
Benzamide, N-[[4-[[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2S)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- | [CAS]
2383086-06-2 | [Synonyms]
Benzamide, N-[[4-[[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2S)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- | [Molecular Formula]
C49H59N7O7S | [MOL File]
2383086-06-2.mol | [Molecular Weight]
890.1 |
| Hazard Information | Back Directory | [Description]
Sonrotoclax is an antineoplastic. | [Uses]
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1]. | [in vivo]
Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; daily, for 42 d; female NCG mice with acute lymphoblastic leukemia (ALL) xenografts) has antineoplastic activity and inhibits tumor growth[1]. | Animal Model: | Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts[1] | | Dosage: | 5, 15, 50 mg/kg | | Administration: | oral administration; daily, for 42 days | | Result: | Inhibited tumor growth in a dose-dependent manner. |
| [References]
[1] Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1. |
|
|